Tejnaksh Healthcare Ltd (TEJNAKSH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Tejnaksh Healthcare Ltd on NSE and BSE, with an AI summary of each filing.
Respected Sir/Madam, Please find attached the letter for your reference and record Thanks
Others (Uncategorized) · 02 Nov 2026, 8:36 am
Tejnaksh Healthcare MD Appointed Global Mentor for ES-TIP 2027 Program Tejnaksh Healthcare announced on 2nd Nov'26 that its Managing Director, Dr. Ashish V. Rawandale-Patil, has been selected as a mentor for the Endourological Society’s Technology Innovation Program 2027 (ES-TIP 2027). The program supports medical innovations and commercialization for improved patient care. Notably, Dr. Rawandale-Patil is the sole non-US urologist appointed alongside three US-based mentors. The company expects this prestigious international recognition to significantly boost its global visibility, reputation, and standing in advanced urological healthcare and medical innovation.
Respected Madam/Sir, Please find attached letter. Thanks & Regards
Others (Uncategorized) · 24 Oct 2026, 11:37 pm
Tejnaksh Healthcare Validates Pflow Device in Indian Journal of Urology Tejnaksh Healthcare announced that a peer-reviewed research paper validating its portable uroflowmetry device, Pflow™, has been published in the Indian Journal of Urology. The multicentric prospective study involved 372 patients across two tertiary urology centers, demonstrating strong agreement with conventional gravimetric uroflowmetry parameters. Authored partly by Managing Director Dr. Ashish Rawandale-Patil and Director Dr. Preeti Rawandale, the publication provides independent scientific validation for the technology—previously featured on Shark Tank India Season 2—supporting its clinical adoption as a patient-friendly uroflowmetry solution.
Respected Madam/Sir, Please find attached Reappointment of Independent Director Suhas Thorat for the second term.
Change in Management · 02 Oct 2026, 4:24 am
Tejnaksh Healthcare Approves Re-Appointment of Independent Director Suhas Thorat Tejnaksh Healthcare Limited's shareholders approved the re-appointment of Mr. Suhas Vasantrao Thorat (DIN: 09241231) as an Independent Director for a second consecutive term of five years during the 18th Annual General Meeting held on 29th Sep'26. Mr. Thorat, originally appointed on 14th Aug'21, brings over 15 years of managerial and administrative experience. He holds no shares in the company, has no inter-se relationships with other directors, and holds no other directorships or committee memberships in listed or public entities.
Respected Madam/Sir, Please find attached Scrutinizer Report.
Annual General Meeting · 02 Oct 2026, 3:56 am
Tejnaksh Healthcare Shareholders Approve All Resolutions at 19th AGM Tejnaksh Healthcare Limited announced that shareholders approved all four resolutions with a 100% majority of valid votes polled at its 19th AGM held on 29th Sep'26. Key approvals include the adoption of audited financial statements for the fiscal year ended 31st Mar'26, the re-appointment of director Sanjay Bhikajirao Khatal, the re-appointment of Suhas Vasantrao Thorat as Independent Director for a second five-year term, and the approval of material Related Party Transactions, wherein interested promoter votes totaling 14,967,134 shares were treated as invalid.
Please refer letter attached for AGM proceeding held on 29th September 2026
Annual General Meeting · 29 Sept 2026, 9:36 pm
Dear Sir / Madam With reference to captioned subject find enclosed herewith Annual Report of the Company for the F.Y. 2025-26 Kindly take the same on your record.
Others (Uncategorized) · 04 Sept 2026, 6:44 pm
This to inform that the 19th Annual General meeting to be held on 29th September 2026. Notice is attached for your reference
Annual General Meeting · 04 Sept 2026, 6:28 pm
Please find attached unaudited FS as of June 26
Financial Result · 14 Aug 2026, 12:22 am
Tejnaksh Healthcare Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 265 (+0.5% YoY | +4.0% QoQ) ■ EBITDA: 69.0 (+14.8% YoY | -3.3% QoQ) ■ EBITDA Margin (%): 26.0 (+322 bps YoY | -194 bps QoQ) ■ PAT: 27.1 (+8.1% YoY | -25.0% QoQ) ■ EPS (INR): 0.13 (+8.3% YoY | -23.5% QoQ)
In continuation of our Letter dated 08th August, 2026 we wish to inform you that a meeting oft he Board of Directors of the Company was held on Thursday, 13th August, 2026 at 03:00 pm ....
Outcome · 14 Aug 2026, 12:09 am
Tejnaksh Healthcare Q1FY27 Results & Board Update Tejnaksh Healthcare reported Q1FY27 results on 13-Aug'26. On a standalone basis, revenue from operations grew 3.5% YoY to ₹184.29 lakhs, while profit after tax fell 13.7% YoY to ₹29.11 lakhs. Consolidated revenue rose 0.5% YoY to ₹265.39 lakhs, with profit after tax declining 22.4% YoY to ₹26.07 lakhs. The Board also approved the reappointment of Mr. Suhas Vasantrao Thorat as a Non-Executive Independent Director for a second term, subject to shareholder approval.
Tejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve We hereby inform you that ....
Intimation · 13 Aug 2026, 5:30 am
Tejnaksh Healthcare Board Meeting Set for Q1 Results and Director Reappointment Tejnaksh Healthcare's Board of Directors will meet on 13th Aug'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th Jun'26. The agenda also includes the proposed reappointment of Mr. Suhas Vasantrao Thorat as an Independent Director for a second term. This reappointment is subject to shareholder approval via a special resolution. The trading window for dealing in company shares has been closed since 25th Jun'26 and will reopen 48 hours after the results are declared.
Please find enclosed Audited financial results for March 2026
Financial Result · 30 May 2026, 11:29 pm
Tejnaksh Healthcare FY26 Results: Net Profit Halves Despite Stable Revenue For FY26, Tejnaksh Healthcare reported a 47.1% YoY decline in consolidated net profit to ₹118.11 lakhs, while revenue from operations fell 16.3% to ₹1,078.69 lakhs. The company's profit before tax decreased by 48.4% YoY to ₹164.62 lakhs. Q4 FY26 net profit was ₹34.86 lakhs, down 17.6% YoY. Total expenses for FY26 decreased slightly by 5.8% to ₹953.37 lakhs. On a standalone basis, FY26 net profit fell 47.4% YoY to ₹137.98 lakhs. The Board approved these results on 30-May-26.
1.Considered and approved Audited Financial Results (Standalone & Consolidated) for the quarter and Year ended on March 31, 2026, and Auditors Report thereon;2. A declaration pursuant to ....
Outcome · 30 May 2026, 11:06 pm
Tejnaksh Healthcare Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 255 (-20.6% YoY | -2.4% QoQ) ■ EBITDA: 71.3 (+0.8% YoY | +3.4% QoQ) ■ EBITDA Margin (%): 27.9 (+592 bps YoY | +158 bps QoQ) ■ PAT: 36.1 (-29.0% YoY | +18.4% QoQ) ■ EPS (INR): 0.17 (-19.0% YoY | +21.4% QoQ)
Tejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 30 May 2026, 5:30 am
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 29 Apr 2026, 1:27 am
Tejnaksh Healthcare Confirms It Is Not a "Large Corporate" Tejnaksh Healthcare Limited confirmed on 28 Apr'26 that it does not qualify as a "Large Corporate" under SEBI's framework. This exempts the company from mandatory fund-raising requirements through debt securities. The disclosure stated its outstanding borrowing was Nil as of 31 Mar'26, and consequently, it had no credit rating for the previous fiscal year. This classification signifies a lower debt-raising obligation, which is relevant for assessing the company's capital structure and potential financing activities.
Respected Sir/Madam, Please find our reply attached below.
Others (Uncategorized) · 10 Apr 2026, 4:54 am
Tejnaksh Healthcare Denies Undisclosed Information Driving Share Price Tejnaksh Healthcare, in a filing on 09-Apr-26, responded to a BSE clarification request regarding its significant share price movement. The company confirmed it has not withheld any material information or disclosures that could explain the volatility. It stated all required information under SEBI regulations has been duly disclosed. Tejnaksh attributed the recent price movement purely to market conditions and considers it to be entirely market-driven, asserting there are no undisclosed company-specific events influencing the stock's performance.
The Exchange has sought clarification from Tejnaksh Healthcare Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 09 Apr 2026, 12:38 am
Please refer standalone and consolidated unaudited result for the quarter ended 31st December 2025.
Financial Result · 07 Feb 2026, 11:46 pm
Tejnaksh Healthcare Q3 FY26 Net Profit Declines Amid Lower Revenue Tejnaksh Healthcare reported a consolidated net profit of ₹28.82 lakhs for Q3 FY26, a 48.1% YoY and 13.0% QoQ decline. Revenue from operations fell 18.0% YoY to ₹261.62 lakhs. On a standalone basis, Q3 net profit was ₹22.78 lakhs, down 68.3% YoY. The Board approved these unaudited results on 07 Feb'26. Basic EPS for the quarter stood at ₹0.14, compared to ₹0.38 in the prior year quarter. Total expenses decreased slightly by 2.8% YoY to ₹232.99 lakhs.
In continuation of our Letter dated 2th February, 2026 we wish to inform you that a meeting of the Board of Directors of the Company was held on Saturday, 7th February, 2026 at Shop No 1 ....
Outcome · 07 Feb 2026, 11:35 pm
TEJNAKSH HEALTHCARE LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) ■ Revenue: 262 (-18.0% YoY | -12.2% QoQ) ■ EBITDA: 68.9 (-39.3% YoY | -11.0% QoQ) ■ EBITDA Margin (%): 26.3 (-926 bps YoY | +35 bps QoQ) ■ PAT: 30.5 (-50.0% YoY | -2.3% QoQ) ■ EPS (INR): 0.14 (-63.2% YoY | -6.7% QoQ)
Tejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 07 Feb 2026, 5:30 am
Tejnaksh Healthcare Sets Board Meeting for Q3 FY26 Results Tejnaksh Healthcare (BSE: 539428) will hold a Board of Directors meeting on 07 Feb'26. The agenda includes the consideration and approval of unaudited standalone and consolidated financial results for the quarter ending 31 Dec'25. The company's trading window for dealing in its shares has been closed since 28 Dec'25 and will reopen 48 hours after the results are declared.
Please find enclosed financial result for the quarter ended 30th September 2025
Financial Result · 09 Nov 2025, 3:44 am
In continuation of our Letter dated 1st November, 2025 we wish to inform you that a meeting of the Board of Directors of the Company was held on Saturday, 8th November, 2025 at Shop No ....
Outcome · 09 Nov 2025, 3:36 am
Tejnaksh Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2025 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 08 Nov 2025, 5:30 am
Please refer letter attached for the change of management
Change in Management · 29 Sept 2025, 1:24 am
Please refer letter attached for the Change in Management
Change in Management · 29 Sept 2025, 1:23 am
Please Refer Scrutinizer Report Attached
Annual General Meeting · 29 Sept 2025, 1:12 am